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We previously showed that the T cell activation inhibitor, mitochondrial (Tcaim) is highly expressed in grafts of tolerance-
developing transplant recipients and that the encoded protein is localized within mitochondria. In this study, we show that
CD11c+ dendritic cells (DCs), as main producers of TCAIM, downregulate Tcaim expression after LPS stimulation or in vivo
alloantigen challenge. LPS-stimulated TCAIM-overexpressing bone marrow–derived DC (BMDCs) have a reduced capacity to
induce proliferation of and cytokine expression by cocultured allogeneic T cells; this is not due to diminished upregulation of
MHC or costimulatory molecules. Transcriptional profiling also revealed normal LPS-mediated upregulation of the majority of
genes involved in TLR signaling. However, TCAIM BMDCs did not induce Il2 mRNA expression upon LPS stimulation in
comparison with Control-BMDCs. In addition, TCAIM overexpression abolished LPS-mediated Ca2+ influx and mitochondrial
reactive oxygen species formation. Addition of IL-2 to BMDC–T cell cocultures restored the priming capacity of TCAIM BMDCs
for cocultured allogeneic CD8+ T cells. Furthermore, BMDCs of IL-2–deficient mice showed similarly abolished LPS-induced
T cell priming as TCAIM-overexpressing wild type BMDCs. Thus, TCAIM interferes with TLR4 signaling in BMDCs and
subsequently impairs their T cell priming capacity, which supports its role for tolerance induction. The Journal of Immunology,
2015, 194: 3136–3146.
T
cell activation inhibitor, mitochondrial (Tcaim; also
known as Toag-1) is highly expressed in graft and blood
of tolerance-developing allogeneic kidney and heart graft
recipients. In contrast, 3–5 days prior to graft rejection Tcaim
mRNA is downregulated up to 10-fold in both compartments (1,
2). TCAIM is highly conserved among different species, but no
homologies to protein families of known functions were detect-
able. The protein contains a mitochondrial leader sequence and
a J-domain within the N- and C terminus, respectively. So far little
is known about the specific function of TCAIM. It is highly
expressed in CD11c+ dendritic cells (DCs) and CD4+ T cells (1).
Keeren et al. (3) showed that TCAIM is exclusively localized
within mitochondria. Increasing data identified mitochondria to be
crucial for innate immune signaling. West et al. (4) demonstrated
that TNF receptor associated factor (TRAF6) translocates to mi-
tochondria in macrophages after TLR1/2/4 stimulation. Subse-
quently, TRAF6 ubiquitinates the mitochondrial protein evo-
lutionarily conserved signaling intermediate in Toll pathway
(ECSIT) and thereby induces mitochondrial reactive oxygen
species (mROS) production (4). ECSIT is involved in complex I
assembly (5), which is the main producer of ROS (6). mROS
potentiate MAPK signaling by inactivating MAPK phosphatases
(7). Consequently, protein-modification by ROS can result in
a variety of functional changes, such as activation, inactivation, or
multimerization of proteins (8).
As professional Ag-presenting cells, DCs communicate between
innate and adaptive immunity. Upon activation within the tissue,
they migrate to draining lymph nodes. Within the lymph nodes,
DCs activate Ag-specific T cells because of their high expression
levels of costimulatory proteins (e.g., CD86, CD80), MHC class II
(MHC-II) molecules and increased secretion of proinflammatory
cytokines (9). It has also been reported that DCs are able to
produce IL-2 early upon TLR-mediated activation (10, 11). This
might explain the high T cell priming capacity of DCs, because
they are supposed to be the only IL-2–producing cells in the
myeloid compartment (12, 13). Il2 expression is initiated upon
activation of NFAT, which in turn is controlled via dephosphor-
ylation by calcineurin. In DCs, calcineurin is activated by an in-
creased intracellular Ca2+ concentration, initiated by CD14
signaling or Dectin-1 ligand binding (14–16).
We studied the effect of Tcaim overexpression on the priming
capacity of LPS-matured murine bone marrow–derived DCs
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(TCAIM-BMDCs) as compared with control transduced BMDCs
(Control-BMDCs). We showed that LPS- but not polyinosinic-
polycytidylic acid (poly-IC)–stimulated TCAIM-BMDCs have
a reduced priming capacity for both CD4+ and CD8+ T cells.
Interestingly, this was not due to reduced LPS-mediated up-
regulation of MHC-II and CD86 expression or IL-6 production.
In contrast, TCAIM abolished LPS-mediated Ca2+ influx, mROS
formation and diminished Il2 expression. LPS-mediated Il2 ex-
pression was instrumental for the priming capacity of BMDCs.
Addition of IL-2 restored the LPS-induced T cell priming capacity
of TCAIM-BMDCs for CD8+ T cells. Thus, TCAIM interferes
with crucial LPS-signaling steps at the mitochondria and may
thereby inhibit inflammation.
Materials and Methods
Mice
Male BALB/c (H-2d) and C57BL/6 (H-2b) mice were purchased from
Charles River Laboratories. Mice were 6–8 wk of age and were allowed
free access to food and water. The mice were kept according to German
Guidelines on the use of animals in research (from the Berliner Sents-
verwaltung).
Skin transplantation and DC subset sorting
C57BL/6 mice received a transplant from tail skin of BALB/c mice as
previously reported (17). After 2 and 7 d, spleens and lymph nodes were
collected and DC subset sorted on a FACSAria II cell sorter (BD Bio-
sciences, Heidelberg, Germany) according to the gating strategy depicted
in Supplemental Fig. 1.
Generation of BMDCs
BMDCs were produced using a standard protocol as described by Inaba
et al. (18). Briefly, C57BL/6 bone marrow cells were cultured in six-well
non–tissue-treated culture plates (Falcon) in complete medium (RPMI 1640
with stable glutamine supplemented with 10% superior FBS and 1% peni-
cillin–streptomycin; Biochrome). Recombinant mouse GM-CSF (6 ng/ml;
Miltenyi Biotec) was added, and medium was changed every other day.
Adenoviral transduction
Immature DCs were transduced on day 6 with a TCAIM encoding ade-
novirus (TCAIM-BMDCs) or a control virus encoding Egfp (Control-
BMDCs). To increase the transduction-rate 8 mg/ml Polybrene (Sigma-
Aldrich) was added to the mixture. The mixture was centrifuged for 77
min, 3500 rpm, and 14˚C. Cells were placed carefully for an additional 120
min in the incubator (37˚C, 5% CO2, and 90% humidity). The maturation
was induced on day 7 by adding 1 mg/ml LPS or 50 mg/ml poly-IC for 24 h
(both from Sigma-Aldrich).
Coculture
Lymph node cells of BALB/c mice were harvested. The organs were ho-
mogenized through a 100-mm cell strainer. The cell suspension was filtered
using a 40-mm cell strainer after centrifugation. Cells were used as
alloreactive responder cells in cocultures with LPS-stimulated transduced
C57BL/6 BMDCs. To quantify the proliferation of CD4+ or CD8+ T cells
a maximum of 2 3 107 cells was stained with 10 mM Cell Proliferation
Dye eFluor 450 (CPD450; eBioscience) for 20 min at room temperature in
the dark. Cells were washed once. After mixing BMDCs (4 3 104) and
CPD450-labeled responder cells (5 3 105) in a 96-well plate, cells were
incubated for 5 d. In some cocultures, recombinant mouse IL-2 (Peprotech)
was added in increasing concentrations (20 and 200 ng/ml).
Flow cytometry
Coculture: intracellular cytokine staining. Cells were washed once with
medium and restimulated for 4 h at 37˚C with 1 mg/ml ionomycin and
10 ng/ml PMA (Biotrend Chemikalien). After 2 h, 2 mg/ml Brefeldin A
(Sigma-Aldrich) was added. Cells were stained for live dead using Fixable
Viability Dye eFluor 506 (eBioscience) and subsequently for surface ex-
pression of CD3e, CD4, and CD8a at 4˚C for 20 min. Cells were fixed
and permeabilized with the BD Biosciences Cytofix/Cytoperm Fixation/
Permeabilization Kit. For intracellular staining following Abs were used:
CD3e-FITC, CD4-Pacific Blue, CD8a-allophycocyanin-Cy7, IFNg-allo-
phycocyanin (all from BioLegend), and the staining was performed for
30 min at 4˚C. Samples were measured on an LSR II (BD Biosciences) and
analyzed using the FlowJo software (Tree Star).
Coculture: surface staining and proliferation determination. On day 5 of
coculture CPD450-labeled lymph node cells were harvested carefully.
They were stained for live dead and then for surface expression of
CD3e, CD4, CD8a, and CD44 as described above (CD3e-FITC, CD4-
Alexa Fluor 700, CD8a-allophycocyanin-Cy7, and CD44-PeCy7; all
from BioLegend). Responder cell proliferation was measured by the
dilution of CPD450 intensity. Surface expression and proliferation was
measured on an LSR Fortessa (BD Biosciences) and analyzed using
FlowJo software.
Surface expression
Splenocytes and lymph node cells collected from naive C57BL/6 mice
or transplant recipient mice for sorting of DC subsets were stained for sur-
face expression of a lineage mixture (CD3/CD19/CD49b/F4-80-PB),
CD11c-PerCP, B220-AF700, CD199-PE-Cy7, CD64-allophycocyanin,
Ly6C-FITC, CD4-BV785, CD8a-BV650 (all from BioLegend), and
CD103-PE (eBioscience).
BMDCs were harvested with ice-cold PBS and stained for surface ex-
pression of CD11c, IA(b) and CD86 (CD11c-allophycocyanin, IA(b)-PE
and CD86-Biotin, Streptavidin-PerCP) (all from eBioscience). The cells
were measured on a FACSCalibur (BD Biosciences) and analyzed using
FlowJo software.
Cytokine production
The cytokine concentrations in the supernatants taken 6, 12, and 24 h after
1 mg/ml LPS or 50 mg/ml poly-IC stimulation were determined using
a Cytometric Bead Assay from Bender MedSystem according to the
FlowCytomix Mouse/Rat Basic Kit instructions. We measured TNF-a and
IL-6 on a FACSCalibur (BD Biosciences) and quantified the concentra-
tions using the FlowCytomix Pro software (Bender Medsystem). As the
sensitivity for mouse IL-2 with the CBA technology is low, we used
the Luminex xMAP Technology. Supernatants were treated exactly
according to the Milliplex MAP Kit protocol (Millipore) and were ana-
lyzed with the Bio-Plex200 System (Bio-Rad).
Measurement of mitochondrial membrane potential DC
BMDCs were stimulated for 24 h with 1 mg/ml LPS or not. After a wash-
ing step with prewarmed PBS, BMDCs were incubated with 150 nM
tetramethylrhodamine-methyl ester (TMRM) (Invitrogen) in PBS con-
taining 2% BSA for 15 min at room temperature in the dark. After
a washing step with a 150-pM TMRM solution, cells were stained with
CD11c-allophycocyanin and measured within 30 min on a FACSCalibur
(BD Biosciences). Data were analyzed with FlowJo software.
Measurement of mROS
BMDCs were stimulated for 1 and 3 h with 1 mg/ml LPS or not. After
a washing step with prewarmed PBS, BMDCs were incubated with 5 mM
final concentration MitoSox (Molecular Probes) in HBSS containing 1 nM
calcium, 1 mM magnesium. After a washing step with PBS/10% FCS
cells were additionally stained with CD11c-allophycocyanin and measured
within 30 min on a FACSCalibur (BD Biosciences). Data were analyzed
with FlowJo software.
Ca2+ influx
BMDCs were resuspended in prewarmed cell loading medium (HBSS
containing 1 nM calcium, 1 mM magnesium, 1% FBS, and 0.5% BSA)
and 4 mM probenecid (Santa Cruz). Cells were incubated for 30 min at
37˚C with 2 mg/ml Indo-1 AM (Life Technologies). After two washing
steps with cell loading medium at room temperature, cells were stained at
4˚C with CD11c-allophycocyanin. Cells were rested and warmed to room
temperature before measuring. The LSRFortessa (BD Biosciences) was
used to quantify first the calcium flux without stimulus. Afterwards, the
same cells were stimulated with 10 mg/ml LPS or 1 mg/ml ionomycin and
immediately recorded.
Detection of apoptotic cells
After a surface staining step (CD11c-allophycocyanin), BMDCs were
washed twice with cold PBS. Cell pellets were resuspended in 13Annexin-
V binding Buffer. Cells were stained with Annexin-V-PE and 7-amino-
actinomycin D according to the protocol (Annexin-V-PE Apoptosis De-
tection Kit I; BD Biosciences) and measured within 1 h using an LSRFortessa
(BD Biosciences).
The Journal of Immunology 3137
 by guest on A
pril 4, 2019
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
RT2 profiler PCR array: mouse TLR signaling pathway
microarray
BMDCs were stimulated 2 d after transduction with 1 mg/ml LPS for 1 and
12 h. RNA was extracted using NucleoSpin RNA II (Macherey-Nagel) fol-
lowing manufacturer’s instructions. In total, 3 mg RNA was used for cDNA
synthesis according to the QuantiTect Reverse Transcription (Qiagen) man-
ual. The Mouse Toll-Like Receptor Signaling Pathway Microarray (Qiagen)
was performed following the instructions with some modifications. cDNA
synthesis reaction mix (60 ml) was diluted with 60 ml RNase-free H2O.
Diluted cDNAwas mixed with additional H2O and SYBR Green PCRMaster
Mix (Life Technologies). The experimental mixture (25 ml) was pipetted to
each well of the 96-well PCR array. A two-step cycling program was started
using an ABI 7500 Sequence Detection System. Raw data were analyzed
with 7500 System Software Version 1.3.1.2.1 (ABI). Mouse hypoxanthine
phosphoribosyltransferase (mHprt) was used as a housekeeping gene.
PCA and clustering
All steps of the analysis were performed in R 2.15.0. The quantitative real-
time PCR (QRT-PCR) data were normalized by subtracting the corre-
sponding Ct-values of mHprt as housekeeping gene. The resulting DCt
values of all target genes present on the arrays were used in a principle
component analysis. The calculations were performed by a single value
decomposition of the centered, not-scaled data matrix. The two first
principle components are shown in Fig. 6B. Variances over all samples
were calculated for each target gene. Highly variable genes with a variance
$4 were selected and used in subsequent clustering; therefore, data were
scaled and a hierarchical clustering was performed using euclidean dis-
tances and a complete linkage.
QRT-PCR
RNA from BMDCs stimulated with LPS or poly-IC or from sorted DC
subsets was isolated as described before. Up to 1 mg RNA was used for
cDNA synthesis. QRT-PCR was done with TaqMan Universal PCR Master
Mix (ABI) using FAM-TAMRA as reporter fluorescence and mHprt
(MWG Biotech AG) as a normalizing control. The 7500 Real-Time PCR
system was used to detect gene expression for mouse tcaim or IL-2 (mIl2).
The primer sequences used to quantify mouse tcaim expression have been
published previously (19), whereas the primer sequences used to quantify
mouse mIl2 are as follows: Il2 sense 59-TCGCCAGTCAAGAGCTTCA-
GACAAGCA-39, anti-sense 59-CATGCCGCAGAGGTCCAA-39 (MWG
Biotech AG). Primers applied for the detection of mHprt were reported
previously (1). Each reaction was carried out in duplicate. For evaluation
we used 7500 System SDS Software.
Rotenone treatment of murine BMDCs
Transduced BMDCs were treated on day 7 overnight (14 h) with 1 mM
Rotenone (Enzo Life Sciences). In the morning, complete media was ex-
changed and the BMDCs were stimulated with 1 mg/ml LPS for 24 h or
left unstimulated for coculture experiments. For Il2 mRNA expression
studies, Rotenone-treated cells were left untreated or stimulated with 1 mg/ml
LPS for 1 h.
TF activation reporter array I
One day after transduction cells were seeded in a 96-well white-wall
plate (Greiner Bio-One) at 70% confluency and incubated overnight.
Recombinant baculovirus (30 ml) encoding a construct of a consensus
sequence for one of the following transcription factors NF k-light-chain-
enhancer of activated B cells (NF-kB), NFAT, activating protein-1 (AP1)
or CCAAT/enhancer binding proteins (C/EBP) followed by a luciferase
reporter gene (Signosis) were added directly to the corresponding wells.
Twenty-four hours later, cells were left untreated or were stimulated for 30
min and 3 h with 1 mg/ml LPS. After treatment, the media was carefully
removed and cells were washed with 100 ml PBS. Cells were incubated
with 40 ml passive lysis buffer (Promega) for 15 min at room temperature.
Luciferase Assay Substrate (100 ml; Promega) was added and mixed
gently. Luminescence was measured using Mithras LB 940 (Berthold
Technologies) immediately after substrate addition.
Statistics
Flow cytometry data were analyzed with FlowJo software version 9.4.3. The
analyses were performed using R 2.15.0. We have used two-way ANOVA
with multiple comparisons to analyze the data. Confidence intervals and
adjusted p values were calculated using the Studentized range statistic
(Tukey honest significant difference method). A p value , 0.05 was
considered to be statistically significant (*p # 0.05, **p # 0.01, ***p #
0.001, ****p # 0.0001). Data are expressed as mean 6 SEM if not
mentioned in the figure legends.
Results
DCs downregulate Tcaim expression following in vitro LPS
stimulation or in vivo allogeneic skin transplant challenge
First, we determined whether inflammatory stimuli influence Tcaim
expression in DCs. Therefore, BMDCs were stimulated with LPS
for 1, 3, 6, 12 ,and 24 h, and their TCAIM mRNA expression was
analyzed. As shown in Fig. 1A, LPS stimulation resulted in
a transient significant reduction of Tcaim mRNA expression,
reaching its maximum at 3 h after stimulation.
Next, we investigated whether this also happens in vivo. To this
end, we sorted different DC populations (CD4+, CD8+, CD42
CD82, CD103+, monocyte-derived DCs [moDCs], and plasma-
cytoid DCs; gating strategy shown in Supplemental Fig. 1) from
spleens and lymph nodes of naive C57BL/6 mice and mice 2 and
7 d after receiving a BALB/c skin transplant. CD64+ moDCs were
included because they are supposed to most closely resemble
BMDCs. As can be seen in Fig. 1B, allogeneic skin transplanta-
tion resulted in an early but transient increase in frequencies of
plasmacytoid DCs, whereas we detected a continuous increase in
CD4+, CD103+, and moDCs. Especially those three DC subsets
showed also a downregulation in TCAIM transcription following
transplantation (Fig. 1C). For CD103+ and moDCs this effect was
transient, whereas in CD4+ DCs this effect was even more pro-
nounced 7 d posttransplant.
TCAIM-BMDCs show a reduced T cell priming capacity
To investigate whether the mitochondrial protein TCAIM affects
BMDC function, we overexpressed Tcaim using adenoviral gene
delivery, reaching a significant increase in TCAIM expression es-
pecially upon LPS stimulation (Supplemental Fig. 2).
Enhanced expression of Tcaim in BMDCs resulted in increased
baseline proliferation of cocultured CD8+ T cells (Fig. 2). LPS and
poly-IC stimulation of Control-BMDCs resulted in an increase of
proliferating cocultured allogeneic CD4+ and especially CD8+
T cells (Fig. 2). TCAIM overexpression led to a reduced priming
capacity of LPS-stimulated BMDCs (Fig. 2). We observed a sub-
stantially diminished proliferation and CD44 expression of cocul-
tured CD4+ and CD8+ T cells (Fig. 2). Interestingly, this reduced
priming capacity of TCAIM-BMDCs was specific for LPS-stimu-
lation and not observed upon poly-IC stimulation.
In addition, we analyzed cocultured T cells for their cytokine
production after restimulation with PMA–ionomycin. Again LPS
and to a reduced extent also poly-IC stimulation of Control-
BMDCs increased the frequencies of IFN-g expressing cocul-
tured allogeneic CD4+ and, even more pronounced, CD8+ T cells
(Fig. 3A). We observed reduced IFN-g production of cocultured
CD4+ and CD8+ T cells with LPS-stimulated TCAIM-BMDCs
compared with Control-BMDCs. This reached significance when
applying the Wilcoxon test (p , 0.05), but did not reach signifi-
cance when correcting for multiple comparisons because of low
numbers (n = 4–5). In contrast, poly-IC stimulation of TCAIM-
BMDCs induced a similar increase in IFN-g expressing cocul-
tured allogeneic CD8+ T cells. CD4+ and CD8+ T cells cocultured
with LPS- or poly-IC–stimulated TCAIM- and Control-BMDCs
showed no altered IL-17 and TNF-a production compared with
cocultures with unstimulated BMDCs (Fig. 3B, 3C).
Tcaim overexpression does not affect LPS-mediated MHC-II
and CD86 upregulation
Next, we tested whether an altered surface expression and cytokine
secretion of TCAIM-BMDCs explains the diminished priming
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capacity. No differences in upregulation of MHC-II or CD86
upon LPS and poly-IC stimulation between TCAIM-BMDCs and
Control-BMDCs were detectable. In contrast, baseline CD86 ex-
pression was even slightly increased in unstimulated TCAIM-
BMDCs (Fig. 4A, 4B). In addition, LPS-induced IL-6 secretion
was not affected by TCAIM overexpression (Fig. 4C). TCAIM-
BMDCs did also release TNF-a upon LPS stimulation; however,
we observed reduced TNF-a secretion by 42% in comparison with
Control-BMDCs. Poly-IC–induced TNF-a and IL-6 production
was only slightly lower in TCAIM-BMDC cultures as compared
with Control-BMDCs (Fig. 4C).
TCAIM-BMDCs display abolished release of LPS-induced
mROS
As a mitochondrial protein TCAIM might also interfere with cell
survival and thereby affect the T cell priming capacity of DCs.
Therefore, we analyzed the percentage of apoptotic or necrotic cells
in unstimulated and LPS-stimulated TCAIM- and Control-BMDCs.
FIGURE 1. DCs downregulate Tcaim ex-
pression following in vitro LPS stimulation or
in vivo allogeneic skin transplant challenge. (A)
Tcaim mRNA expression after LPS stimulation.
BMDCs were stimulated with 1 mg/ml LPS for
the indicated time points (0, 1, 3, 6, 12, and
24 h). Shown are the Tcaim mRNA expression
results of n = 4–5 independent experiments, as
mean 6 SEM. (B) Changes in DC subset fre-
quencies in spleen and lymph nodes following
allogeneic skin transplantation (skin Tx). Indi-
cated DC subsets were sorted from spleen and
lymph nodes of naive C57BL/6 mice or mice,
which received an allogeneic BALB/c skin
transplant 2 or 7 d prior to sample collection.
(C) Tcaim mRNA expression of sorted DC
subsets. Shown are the frequencies and Tcaim
mRNA expression results of n = 2–3 indepen-
dent experiments, as mean 6 SEM. Cells of
three mice were pooled per experiment. *p ,
0.05, **p , 0.01, ***p , 0.001, ****p ,
0.0001.
FIGURE 2. TCAIM-BMDCs fail to prime alloreactive
T cells. (A) Representative dot plots showing CD44
expression and proliferation of CD4+ (left panel) and
CD8+ T cells (right panel) cocultured for 5 d with LPS-
or poly-IC-matured or immature TCAIM-BMDCs or
Control-BMDCs. (B) The left panel summarizes the
proliferation results of n = 4–8 independent experiments.
Depicted are the mean 6 SD of the proliferated cells
(CPD negative/low) pregated on living CD3+CD4+ T cells.
The right graph summarizes the proliferation of living
CD3+CD8+ T cells. The mean 6 SEM calculated from
n = 3–6 independent experiments are shown. *p , 0.05,
**p , 0.01, ****p , 0.0001.
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As shown in Fig. 5A, TCAIM overexpression did not affect cell viability
of BMDCs. In addition, recovery of BMDCs in absolute cell num-
bers was not different between TCAIM-BMDCs and Control-BMDCs
(TCAIM-BMDCs: 55% 6 5.7; Control-BMDCs: 55.5% 6 3.4).
ATP and mROS production are dependent on mitochondrial
membrane potential DC. To determine whether LPS-stimulated
TCAIM-BMDCs show an altered DC, we used TMRM. TMRM
is a lipophilic cation that accumulates DC-dependent in negatively
charged mitochondria (20, 21). Fig. 5B shows the percentages
of TMRM accumulation in unstimulated and LPS-stimulated
TCAIM- and Control-BMDCs. Tcaim overexpression showed no
effect on the mitochondrial membrane potential.
In addition, we investigated whether Tcaim overexpression
alters mROS release (Fig. 5C). We measured mROS in TCAIM-
BMDCs and Control-BMDCs, which were left unstimulated or
stimulated with LPS for 1 h and 3 h. TCAIM-BMDCs showed a
significantly diminished mROS production compared with Control-
BMDCs. As described by West et al. (4, 22), we could not detect
mROS induction upon poly-IC stimulation (data not shown).
Gene array analysis reveals abolished LPS-induced Il2
expression in TCAIM-BMDCs
To reveal the underlying mechanism for the diminished T cell
priming capacity of TCAIM-BMDCs, we studied their LPS-in-
duced transcription using a TLR signaling pathway PCR Array.
TCAIM-BMDCs and Control-BMDCs were stimulated for 1 or
12 h with LPS or were left unstimulated. We visualized the results
of three independent experiments using an unsupervised heat map
analysis, meaning that the sample arrangement occurred respec-
tively to expression similarities and not to groups. A clustering
of all unstimulated, 1-h LPS-stimulated, or 12-h LPS-stimulated
samples implied that the stimulatory effect of LPS exceeds gen-
erally the effect of Tcaim overexpression (Fig. 6A). A principal
component analysis, in which triplicates of TCAIM- and Control-
BMDCs of three stimulation time points are depicted, also showed
a uniform distribution of TCAIM- and Control-BMDCs according
to their stimulation (Fig. 6B). Surprisingly, of the 84 genes ana-
lyzed, only expression of Il2 was significantly downregulated in
TCAIM-BMDCs compared with Control-BMDCs. To verify the
array results, we performed QRT-PCR on additional samples. LPS
stimulation of Control-BMDCs resulted in an up to 20-fold up-
regulation of Il2 mRNA expression (Fig. 6C). Already in unsti-
mulated BMDCs, TCAIM overexpression reduced the basal Il2
transcription. LPS-induced Il2 mRNA expression was signifi-
cantly decreased in TCAIM-BMDCs compared with Control-
BMDCs. Il2 mRNA expression was not increased upon poly-IC
stimulation in TCAIM- and Control-BMDCs compared with un-
stimulated cells. Furthermore, we detected a time-dependent increase
in IL-2 protein secretion in supernatants of LPS-stimulated
Control-BMDCs, which we did not observe in supernatants of
LPS-stimulated TCAIM-BMDCs (Fig. 6D).
Il2 transcription in T cells and in DCs is regulated by intra-
cellular Ca2+ increase with subsequent NFAT/NF-kB/AP1 acti-
FIGURE 3. TCAIM-BMDCs induce fewer cytokine
producing alloreactive T cells. (A) The left panel
depicts the results of n = 3–5 independent experiments
for CD4+ T cells and n = 3–4 independent tests for
CD8+ T cells cocultured with allogeneic BMDCs.
Depicted is the percentage of IFN-g–producing living
CD3+CD4+ or CD8+ T cells. The results are shown as
mean 6 SEM; p , 0.05 (Wilcoxon-test) for CD4+ and
CD8+ cocultured with LPS-stimulated TCAIM-
BMDCs versus LPS-stimulated Control-BMDCs. In
addition, the percentages of (B) IL-17– and (C) TNF-a–
producing living CD3+CD4+ (left panels) or CD8+
(right panels) T cells are shown. The mean 6 SEM
calculated from n = 3–5 independent experiments is
shown.
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vation; therefore, we analyzed whether TCAIM overexpression
affects LPS-induced Ca2+ signaling. Fig. 6E shows the intracel-
lular Ca2+ influx after LPS and ionomycin stimulation of TCAIM-
BMDCs and Control-BMDCs. In Control-BMDCs and TCAIM-
BMDCs, we observed a rapid increase of intracellular Ca2+ after
ionomycin stimulation, which was lower in TCAIM-BMDCs.
TCAIM-BMDCs were completely unable to increase free cyto-
solic Ca2+ upon LPS stimulation. This effect was highly repro-
ducible (Fig. 6F).
Addition of IL-2 restores T cell priming capacity of
TCAIM-BMDCs
Next we questioned whether the addition of recombinant mouse
IL-2 (rmIL-2) would restore the diminished T cell priming capacity
of TCAIM-BMDCs. We added 20 or 200 ng/ml rmIL-2 to the co-
culture of LPS-stimulated transduced BMDCs and allogeneic
lymph node cells. We observed a dose-dependent induction of
CD8+ T cell proliferation in cocultures with LPS-matured
TCAIM-BMDCs (Fig. 7A), whereas the addition of rmIL-2 in-
creased but did not normalize proliferation of cocultured CD4+
T cells. The proliferation in cocultures with LPS-stimulated
Control-BMDCs was not affected by the addition of rmIL-2.
Last, we tested whether IL-2 production by BMDCs determines
their T cell priming capacity. Therefore, BMDCs generated from
bone marrow of IL-2–deficient and IL-2+/2 heterozygous control
mice were cocultured with allogeneic lymph node cells. Indeed,
IL-2–deficient BMDCs failed to increase their T cell priming
capacity upon LPS stimulation (Fig. 7B). This failure was more
pronounced for priming of CD8+ T cells as compared with CD4+
T cells.
Inhibition of mROS generating complex I reduces Il2
expression and T cell priming capacity of LPS-stimulated
BMDCs
Rotenone, a systemic complex I inhibitor, was used to inhibit the
mROS production in BMDCs (23), as complex I is one important
source of mROS (6). To evaluate the effect of Rotenone on Il2
mRNA expression, we treated the cells overnight with 1 mM
Rotenone or control medium and then stimulated them for 1 h
with LPS or left them unstimulated. Overnight incubation with
FIGURE 4. Tcaim overexpression does not affect
LPS-mediated MHC-II and CD86 upregulation. (A)
Representative dot plots showing the expression of
MHC-II and CD86 of CD11c+ immature and 24 h LPS-
or poly-IC–matured TCAIM-BMDCs or Control-
BMDCs analyzed by flow cytometry. (B) MHC-II (left
panel) and CD86 (right panel) expression in the per-
centage of CD11c+ cells stimulated with LPS (1 mg/ml)
or poly-IC (50 mg/ml) for 24 h or left unstimulated
TCAIM-BMDCs and Control-BMDCs of n = 5–6 in-
dependent experiments are shown, depicted as mean 6
SD. *p , 0.05, **p , 0.01, ***p , 0.001. (C) Effect
on cytokine release upon Tcaim overexpression. The
graphs show the cytokine production of LPS-stimulated
(1 mg/ml) or poly-IC-stimulated (50 mg/ml) stimulated
BMDCs analyzed using a cytometric bead array.
Supernatants were taken 0, 6, 12, and 24 h after stim-
ulation. The left figure displays the TNF-a secretion of
n = 2–7 independent experiments, whereas the right
graph shows the IL-6 release of n = 1–9 independent
experiments. Results are depicted as mean 6 SEM.
*p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001.
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Rotenone had no effect on Il2 mRNA expression of LPS-
stimulated TCAIM-BMDCs (Fig. 8A). In contrast, Il2 mRNA
expression is considerably attenuated in LPS-stimulated Rotenone-
treated Control-BMDCS. Furthermore, Rotenone-treated LPS-ma-
tured Control-BMDCs had a diminished T cell priming capacity
in comparison with untreated LPS-matured Control-BMDCs (Fig. 8B).
This effect was more prominent for cocultured CD8+ T cells
than for CD4+ T cells. In contrast, Rotenone-treatment of LPS-sti-
mulated TCAIM-BMDCs did not reduce their residual low T cell
priming capacity.
TCAIM alters transcription factor binding activity of NF-kB
and C/EBPb
To obtain insight into the molecular mechanisms of TCAIM-
mediated reduction in IL-2 production and T cell priming ca-
pacity of BMDCs, we have performed preliminary experiments
studying LPS-induced transcription factors activation. TCAIM-
and Control-BMDCs were incubated with baculoviruses encoding
luciferase constructs with transcription factor binding sites for
NFAT, NF-kB, AP1, and C/EBPb. The following day, BMDCs
were stimulated with LPS for 30 min and 3 h, and transcription
factor binding activity was determined with luciferase assay
(Fig. 8C). We detected a low NFAT binding activity in BMDCs,
but we did not observe a difference between TCAIM-BMDCs and
Control-BMDCs. In contrast, we detected a LPS-induced increase
in NF-kB and AP1 binding activity, which was especially lower
for NF-kB in TCAIM-BMDCs. Strikingly, TCAIM-BMDCs dis-
played a transient increase in C/EBPb binding activity, which we
did not observe for Control-BMDCs.
Discussion
In this study, we show that increased expression of TCAIM in
murine BMDCs leads to an impaired LPS-induced priming ca-
pacity for allogeneic CD4+, but even more CD8+ T cells. This was
not due to abolished LPS-mediated upregulation of MHC-II or
CD86 expression. Release of inflammatory cytokines and media-
tors such as IL-6, IL-12, or IL-1 was not affected. However, LPS-
stimulated TCAIM-BMDCs were characterized by a reduced Ca2+
influx, mROS formation, and Il2 expression. Adding IL-2 nor-
malized proliferation of cocultured CD8+ T cells. Furthermore,
IL-2 deficient BMDCs failed to increase priming of cocultured
CD8+ T cells upon LPS stimulation. Interestingly, inhibiting
mROS producing mitochondrial complex I did mimic Tcaim
overexpression as it resulted in reduced LPS-mediated Il2 ex-
pression and T cell priming capacity.
Mitochondria play an important and decisive role in cell sig-
naling. Especially their role in immune cell signaling has gained
much attention in recent years (24, 25). Apart from regulating
apoptosis, mitochondrial release of ROS is instrumental for redox-
sensitive signaling pathways such as activation of MAP kinases,
NF-kB, and AP1 as well as mitochondria are indispensable for
Ca2+ signaling (22, 26–29).
Mitochondria are efficient Ca2+ buffers (30). Because of close
proximity to the plasma membrane, mitochondria can take up
large amounts of inflowing Ca2+, which prevents the inactivation
of calcium release activated Ca2+ (CRAC) channels (31).
Ca2+ is an important second messenger in DCs and its influx occurs
upon PLC-g activation transiently by depleting intracellular stores,
such as the endoplasmic reticulum (ER) or through opening of Ca2+
channels in the plasma membrane. Ca2+ influx is induced by certain
but not all microbial products, such as LPS, CpG, or peptidoglycan,
resulting in a calcineurin-dependent NFAT activation, subsequent
nuclear translocation, and NF-kB activation by degradation of the
NF-kB inhibitor IkB (31). Applying CRAC channel inhibitors results
in a less mature phenotype (32) and a reduced IL-2 secretion (33).
TCAIM as a mitochondrial protein containing a J-domain could
interfere with mitochondrial Ca2+ uptake, as J-domain proteins are
described to be involved in mitochondrial translocases (34, 35).
Mitochondrial calcium uptake can be mediated by the mitochon-
drial calcium uniporter. This transport is supported by the mito-
chondrial membrane potential DC and leads to the production of
mROS (30). Inhibition of the prolonged Ca2+ uptake after LPS-
stimulation in TCAIM-BMDCs by disturbing the Ca2+ transport
into mitochondria could explain the reduced mROS production.
Furthermore, mitochondria play an active part in regulating ino-
sitol triphosphate–mediated Ca2+ release from the ER (36, 37).
Mitochondrial Ca2+ uptake exerts positive feedback effects on
the inositol triphosphate receptor-mediated ER Ca2+ mobilization
(38). Thus, mitochondria can affect both Ca2+ release from the ER
and Ca2+ entry across the plasma membrane, thereby shaping the
FIGURE 5. Tcaim overexpression abolishes release
of mROS, which regulate T cell priming capacity of
BMDCs. (A) Effect of Tcaim overexpression on apo-
ptosis induction. Dot plots of unstimulated or 24 h LPS-
stimulated (1 mg/ml) BMDCs stained for Annexin-Vand
7-actinomycin D are depicted. Results of seven inde-
pendent experiments are shown as mean 6 SEM. The
cells were pregated as CD11c+. (B) Effect on DC upon
Tcaim overexpression. DC was measured 24 h after
LPS-stimulation in CD11c+ TCAIM- and Control-
BMDCs using TMRM. Results are depicted from five
independent experiments as means 6 SEM. (C) MROS
produced by unstimulated or LPS (1 mg/ml) stimulated
TCAIM- and Control-BMDCs after indicated time
points (0, 1, and 3 h) are depicted as means 6 SEM.
Results of 10 independent experiments are shown.
*p , 0.05, **p , 0.01.
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size and duration of the intracellular Ca2+ signal (39). This could
explain that TCAIM-BMDCs showed abolished LPS-mediated
and reduced ionomycin-mediated increase in Ca2+.
Interestingly, we could observe a stronger effect of TCAIM
overexpression on the induction of proliferation and cytokine
production by cocultured CD8+ T cells than by CD4+ T cells.
FIGURE 6. Gene array analysis reveals an abolished Il2 induction in TCAIM-BMDCs. (A) Analysis of gene expression using a mouse TLR signaling
pathway PCR array in Tcaim overexpressing BMDCs upon LPS activation. Unsupervised heat map of three independent experiments, in which TCAIM
(T) overexpressing and control-transduced BMDCs (C) were left unstimulated or stimulated for 1 and 12 h with 1 mg/ml LPS. From the 84 genes
analyzed, the expression of the 16 genes shown was regulated upon LPS stimulation, normalized to hypoxanthine-guanine phosphoribosyltransferase
(HPRT), when setting the variance threshold (v . 4) high. (B) Depicted is a principal component analysis of three independent experiments. Shown are
the single experiment gene expression results normalized to HPRT of TCAIM-BMDCs (triangle) or Control-BMDCs (circle) at the following time
points: 1 h (orange) and 12 h (red) LPS stimulated or unstimulated (blue). (C) Il2 mRNA expression after LPS and poly-IC stimulation. TCAIM- and
Control-BMDCs were stimulated with 1 mg/ml LPS or 50 mg/ml poly-IC for the indicated time points (0, 1, and 12 h). Shown are the Il2 mRNA
expression results of n = 4–8 independent experiments, as mean 6 SEM. **p , 0.01, ***p , 0.001. (D) IL-2 protein secretion into supernatants of
LPS-stimulated TCAIM- and Control-BMDCs. Shown are the results of eight independent experiments as mean 6 SEM. (E) Indo-1–labeled TCAIM-
or Control-BMDCs were stimulated with 10 mg/ml LPS or 1 mg/ml ionomycin. Ca2+ influx is illustrated as the ratio of Indo-1 violet and Indo-1 blue
over time. Depicted are exemplary histograms of pregated CD11c+ BMDCs. (F) Summary of peak influx levels of three independent Ca2+ influx
measurements.
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Shumilina et al. (31) described that the calcium influx at the
immunologic synapse is dependent on the type of T cell con-
tacting the DC. When the DC interacted with alloreactive CD8+
T cells, the Ca2+ concentration rose within DCs. In contrast, when
the DC formed a synapse with alloreactive CD4+ T cells, only an
increase of Ca2+ in the T cells was detectable (31, 40, 41). Thus,
the more profound defect in proliferation and IFN-g by cocultured
CD8+ T cells is perhaps due to the completely abolished calcium
influx in TCAIM-BMDCs.
It is well known that during priming of naive CD8+ T cells
presence of CD4+ T cells is critical (42, 43). Wolkers et al.
showed that in the absence of CD4+ T cells, the addition of ex-
ogenous IL-2 markedly increased the secondary expansion of and
IFN-g production by CD8+ T cells (44). The maximal expansion
was achieved when using IL-2 concentrations between 10 and 100
ng/ml (44). This finding is in accordance with our data, because
in our cocultures with LPS-stimulated TCAIM-BMDCs CD4+,
T cells were not activated compared with cocultures with LPS-
stimulated Control-BMDCs, but the addition of 20 to 200 ng/ml
IL-2 could normalize proliferation of CD8+ T cells.
Considering that TCAIM-BMDCs showed a reduced Ca2+
influx and thereby a nearly abolished IL-2 secretion after LPS-
stimulation, it is not surprising that it affected especially the
priming of CD8+ T cells and to a lower extent of CD4+ T cells
(45). Indeed, the addition of IL-2 to cocultures of TCAIM-
BMDCs with allogeneic T cells is able to restore proliferation
of CD8+ T cells to nearly normal levels, whereas the effect was
not as evident for CD4+ T cells.
As pointed out earlier, Ca2+ influx accelerates the generation of
mROS (30). Furthermore, triggering of certain TLRs in immune
cells results in formation of mROS important for bactericidal
activity and for regulation of redox-sensitive signaling pathways
regulating cytokine release and Ag-presenting capacity (22, 26). It
has been shown that ROS production in DCs upon communication
with cocultured T cells determines their Ag-presentation capacity
(46, 47). In those studies, scavenging of ROS by antioxidants,
FIGURE 7. The addition of IL-2 can restore T cell
priming capacity of TCAIM-BMDCs. (A) Representa-
tive dot plots showing CD44 expression and prolifera-
tion (CPD eFluor450), 5 d after cocultures of 5 3 105
BALB/c lymph node cells and 4 3 104 LPS-matured
C57BL/6 TCAIM-BMDCs and Control-BMDCs upon
the addition of 20 or 200 ng/ml recombinant mouse IL-
2, are depicted. (B) Representative dot plots showing
CD44 expression and IFN-g production of living CD3+
CD4+ or CD8+ T cells after PMA/ionomycin restim-
ulation; 5 3 105 BALB/c lymph node cells were
cocultured for 5 d with 4 3 104 unstimulated or LPS-
matured IL-2+/2 heterozygous or IL-2–deficient Con-
trol-BMDCs and TCAIM-BMDCs.
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resulted in reduced release of inflammatory cytokines such as IL-
6, but also abrogated induction of MHC and costimulatory mol-
ecules. We showed that the Tcaim overexpression in BMDCs,
which completely abolished LPS-induced Ca2+ influx and im-
paired mROS production, was associated with diminished T cell
priming capacity. In contrast to the findings above, this finding
was not associated with reduced surface expression of MHC and
costimulatory molecules or production of IL-6. This may be due to
a more specific action of TCAIM on mROS, whereas scavenging
antioxidants can also act on other enzymes generating ROS.
The effects of Tcaim overexpression on the T cell priming ca-
pacity were limited to LPS stimulation and were not observed
upon poly-IC stimulation. This result further supports our hy-
pothesis that TCAIM effects are mediated by inhibiting Ca2+ in-
flux and mROS production, as we and others have observed that
stimulation of BMDCs with TLR3 ligands such as poly-IC do not
elicit either Ca2+ influx or mROS production (4, 15, 48, 49).
In conjunction with the diminished LPS-mediated Ca2+ influx
and mROS production, we observed a reduced NF-kB but in-
creased C/EBPb binding activity. This observation might explain,
on the molecular level, why TCAIM-BMDCs show reduced LPS-
induced IL-2 expression, because NF-kB is well known to control
Il2 transcription positively (50, 51). In contrast, C/EBPb was shown
to influence Il2 transcription negatively, at least in T cells (52).
Our investigations did not completely explain how increased
Tcaim expression abolishes the priming capacity of BMDCs for
cocultured allogeneic CD4+ T cells, as addition of IL-2 did en-
hance but not normalize T cell proliferation. In addition to testing
IL-2, we tested other g-chain signaling cytokines, such as IL-15.
We could neither detect an LPS-induced increase of IL-15 ex-
pression nor did addition of IL-15 restore T cell proliferation (data
not shown).
Thus, the mitochondrial protein TCAIM diminishes the T cell
priming capacity of BMDCs, in particular for CD8+ T cells, by
inhibiting LPS-mediated Ca2+ influx, mROS formation, NF-kB,
and especially Il2 expression.
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Rotenone-treated (1 mM) and 24 h LPS-matured (1 mg/
ml) TCAIM-BMDCs and Control-BMDCs. The cells
are pregated for living CD3+CD4+ or CD3+CD8+
T cells. (C) TCAIM alters transcription factor binding
activity of AP1, NF-kB, and C/EBPb. TCAIM- and
Control-BMDCs were incubated with baculoviruses
encoding a construct of a consensus sequence for one
of the following transcription factors: NF-kB, NFAT,
AP1, or C/BEP followed by a luciferase reporter gene.
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